AstraZeneca-Daiichi Sankyo Enhertu gets USFDA Breakthrough Therapy Designation in HER2-positive early breast cancer Ruchika Sharma22 Dec 2025 1:30 PM ISTCambridge: AstraZeneca and Daiichi Sankyo has announced that Enhertu (trastuzumab deruxtecan) has been granted Breakthrough Therapy Designation (BTD)...
Astrazeneca Saphnelo approved in EU for subcutaneous self-administration for systemic lupus erythematosus adults Ruchika Sharma21 Dec 2025 11:30 AM ISTCambridge: AstraZeneca has announced that Saphnelo (anifrolumab) has been approved in the European Union (EU) for subcutaneous...
AstraZeneca Pharma India wins CDSCO permission to import breast cancer drug Datverzo Ruchika Sharma18 Dec 2025 3:15 PM ISTBangalore: AstraZeneca Pharma India Limited has received permission from the Central Drugs Standard Control Organization (CDSCO),...
AstraZeneca-Daiichi Sankyo Enhertu Combo wins USFDA approval for 1st-line HER2-Positive Metastatic Breast Cancer Ruchika Sharma16 Dec 2025 12:30 PM ISTCambridge: AstraZeneca and Daiichi Sankyo's Enhertu (trastuzumab deruxtecan) in combination with pertuzumab has been approved in the US for...
Astrazeneca Baxdrostat application accepted for priority review by USFDA for hard-to-control hypertension Ruchika Sharma3 Dec 2025 11:30 AM ISTCambridge: AstraZeneca has announced that its New Drug Application (NDA) for baxdrostat has been accepted for Priority Review by the US Food and...
AstraZeneca Imfinzi gets USFDA okay for early gastric and gastroesophageal cancers Ruchika Sharma26 Nov 2025 3:35 PM ISTCambridge: AstraZeneca has announced that Imfinzi (durvalumab) in combination with standard-of-care FLOT chemotherapy (fluorouracil, leucovorin,...
Yashoda Hospitals-Hitech city launches AI-enabled lung nodule clinic Kajal Rajput26 Nov 2025 9:45 AM ISTHyderabad: Yashoda Hospital, Hitech City, in collaboration with Qure.ai and AstraZeneca, has launched an advanced Artificial Intelligence (AI)-powered...
Alexion, AstraZeneca Rare Disease Koselugo gets USFDA nod for neurofibromatosis type 1 Ruchika Sharma20 Nov 2025 5:00 PM ISTAlexion, AstraZeneca Rare Disease has received approval from the USFDA for Koselugo (selumetinib), an oral, selective MEK inhibitor for the...
AstraZeneca Gets SEC Nod to Update Lokelma Prescribing Information for Hyperkalemia Treatment Susmita Roy3 Nov 2025 7:08 PM ISTNew Delhi: The Subject Expert Committee (SEC) functioning under the Central Drugs Standard Control Organisation (CDSCO) has recommended approval for...
Koselugo approved in EU for plexiform neurofibromas in adults with neurofibromatosis type 1: AstraZeneca Ruchika Sharma29 Oct 2025 10:30 AM ISTAlexion, AstraZeneca Rare Disease's Koselugo (selumetinib), an oral, selective MEK inhibitor, has been approved in the European Union (EU) for...
FDA Approves Tezspire for Chronic Rhinosinusitis with Nasal Polyps Dr. Kamal Kant Kohli24 Oct 2025 8:15 PM ISTThe FDA has approved Tezspire (tezepelumab-ekko), a biologic therapy by Amgen and AstraZeneca, as an add-on maintenance treatment for patients aged 12...
AstraZeneca Tezspire approved in EU for chronic rhinosinusitis with nasal polyps Ruchika Sharma23 Oct 2025 11:45 AM ISTAstraZeneca and Amgen's Tezspire (tezepelumab) has been approved in the European Union (EU) as an add-on therapy with intranasal corticosteroids...
